Contributions
Abstract: EP1448
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Background: Pain is a frequent symptom in aquaporin-4-IgG-positive and antibody-negative neuromyelitis optica spectrum disorders (AQP4-NMOSD/ ABneg-NMOSD). Data on pain in MOG-IgG associated neuromyelitis optica spectrum disorders (MOG-NMOSD) are scarce.
Objective: To investigate pain in MOG-NMOSD in comparison to AQP4- and ABnegNMOSD.
Methods: Forty-nine patients with MOG- (n=14), AQP4- (n=29), and ABneg- (n=6) NMOSD were included in this cross-sectional analysis from an ongoing observational study of patients with NMOSD and related disorders. We identified spinal cord lesions in MRI, assessed pain by PainDETECT and McGill Pain Questionnaire, quality of life by Short Form Health Survey, and depression by Beck's Depression Inventory.
Results: Twelve MOG-NMOSD patients (86%), 24 AQP4-NMOSD patients (83%), and all ABneg-NMOSD patients (100%) suffered from pain. MOG-NMOSD patients had mostly neuropathic pain and headache; AQP4- and ABneg-NMOSD patients had mostly neuropathic pain. A history of myelitis was less frequent in MOG-NMOSD than in AQP4-NMOSD patients. Pain influenced quality of life in all patients. Thirty-six percent of patients with pain received pain medication; none of them were free of pain.
Conclusions: Pain is a frequent symptom of patients with MOG-NMOSD and as important as in AQP4- and ABneg-NMOSD. Despite its impact on quality-of-life, pain is insufficiently alleviated by medication.
Disclosure: S Asseyer: nothing to disclose. F Schmidt received speaker honoraria from Genzyme. C Chien: nothing to disclose. M Scheel holds a patent for manufacturing of phantoms for computed tomography imaging and received research support from Federal Ministry of Economics and Technology. J Bellmann-Strobl received travel funding and speaking fees from Bayer Healthcare, Sanofi-Aventis/Genzyme, Merck, and Teva Pharmaceuticals. K Ruprecht served on scientific advisory boards for Sanofi-Aventis/Genzyme, Novartis, and Roche; received travel funding and/or speaker honoraria from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi Aventis/Genzyme, Teva Pharmaceuticals, Novartis, and Guthy Jackson Charitable Foundation; is an academic editor for PLoS ONE; receives publishing royalties from Elsevier; and received research support from Novartis, Merck Serono and German Ministry of Education and Research. AU Brandt is cofounder and shareholder of Motognosis and Nocturne. He is named as inventor on several patent applications regarding MS serum biomarkers, OCT image analysis and perceptive visual computing. F Paul received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology®; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, Alexion; received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA.
Abstract: EP1448
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Background: Pain is a frequent symptom in aquaporin-4-IgG-positive and antibody-negative neuromyelitis optica spectrum disorders (AQP4-NMOSD/ ABneg-NMOSD). Data on pain in MOG-IgG associated neuromyelitis optica spectrum disorders (MOG-NMOSD) are scarce.
Objective: To investigate pain in MOG-NMOSD in comparison to AQP4- and ABnegNMOSD.
Methods: Forty-nine patients with MOG- (n=14), AQP4- (n=29), and ABneg- (n=6) NMOSD were included in this cross-sectional analysis from an ongoing observational study of patients with NMOSD and related disorders. We identified spinal cord lesions in MRI, assessed pain by PainDETECT and McGill Pain Questionnaire, quality of life by Short Form Health Survey, and depression by Beck's Depression Inventory.
Results: Twelve MOG-NMOSD patients (86%), 24 AQP4-NMOSD patients (83%), and all ABneg-NMOSD patients (100%) suffered from pain. MOG-NMOSD patients had mostly neuropathic pain and headache; AQP4- and ABneg-NMOSD patients had mostly neuropathic pain. A history of myelitis was less frequent in MOG-NMOSD than in AQP4-NMOSD patients. Pain influenced quality of life in all patients. Thirty-six percent of patients with pain received pain medication; none of them were free of pain.
Conclusions: Pain is a frequent symptom of patients with MOG-NMOSD and as important as in AQP4- and ABneg-NMOSD. Despite its impact on quality-of-life, pain is insufficiently alleviated by medication.
Disclosure: S Asseyer: nothing to disclose. F Schmidt received speaker honoraria from Genzyme. C Chien: nothing to disclose. M Scheel holds a patent for manufacturing of phantoms for computed tomography imaging and received research support from Federal Ministry of Economics and Technology. J Bellmann-Strobl received travel funding and speaking fees from Bayer Healthcare, Sanofi-Aventis/Genzyme, Merck, and Teva Pharmaceuticals. K Ruprecht served on scientific advisory boards for Sanofi-Aventis/Genzyme, Novartis, and Roche; received travel funding and/or speaker honoraria from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi Aventis/Genzyme, Teva Pharmaceuticals, Novartis, and Guthy Jackson Charitable Foundation; is an academic editor for PLoS ONE; receives publishing royalties from Elsevier; and received research support from Novartis, Merck Serono and German Ministry of Education and Research. AU Brandt is cofounder and shareholder of Motognosis and Nocturne. He is named as inventor on several patent applications regarding MS serum biomarkers, OCT image analysis and perceptive visual computing. F Paul received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology®; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, Alexion; received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA.